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The Objective of this work was to formulate and 
evaluate captopril gel to assess its suitability for transdermal 
delivery by passive and iontophoresis. A polymer gel was 
prepared using hydroxypropyl methyl cellulose and in vitro 
skin permeability was assessed in full thickness skin of rabbits 
and pigs. For in vivo studies New Zealand rabbits were used. 
In vitro passive permeation was carried out in Franz diffusion 
cell but for iontophoresis, diffusion cell was modified according 
to Glikfield design. Iontophoresis was performed at a current 
density of 0.5 mA/cm2 via silver /silver chloride electrodes 
with passive controls but for in vivo study current density was 
reduced to 0.1 mA/cm2. Blood samples were analyzed for 
drug content by HPLC.  Results of the in vitro study indicated 
that iontophoresis considerably increased the permeation rate 
of captopril compared to passive controls in both the skin 
types (P<0.01). The plasma concentration of captopril was 
significantly higher (P<0.001) than that obtained in the 
passive controls. Results showed that the target permeation 
rates for captopril could be achieved with the aid of 
iontophoresis by increasing the area in an appreciable range.   
 
Key words:  Captopril, iontophoresis, transdermal, Rabbit, Pigskin, 
in vitro, in vivo. 
 
INTRODUCTION 
If we analyze the history of human 
suffering, we observe that diseases and 
compulsions imposed by diseased states are 
considered to be a greater enemy to mankind 
rather than the death. Naturally, the ultimate 
aim of every therapy is to restore the normalcy 
of life, but ironically sometimes, the 
requirements of treatment are such that the 
normal rhythm of life is disturbed. Today most 
of drugs are taken orally and are found not to 
be as effective as desired. To improve such 
characters transdermal drug delivery system was 
emerged. To achieve and maintain drug 
concentration above the minimum therapeutic 
level it is the need of transdermal system to 
overcome the barrier properties of skin.  
Iontophoresis is a form of transdermal delivery 
that use in electric field to enhances the 
movement of small, poorly absorbed ionic drug 
across the skin in controlled and program-
mable manner (Nair and Panchagnula, 2003; 
Kalia et al., 2004; Zakzewski et al., 1992).              
The enhancement of drug due to this method 
results from a number of possible mechanisms 
including the ion-electric field interaction 
(electro repulsion), convective flow (electro-
osmosis) and current-induced (Wang et al., 
2004; Pillai et al., 2004) increase in skin 
permeability. 
Captopril is an oral drug and a member 
of a class of drugs called angiotensin converting 
enzyme (ACE) inhibitors. ACE inhibitors are 
used for treating high blood pressure, heart 
failure, and for preventing kidney failure due to 
high blood pressure and diabetes. It has a short 
elimination half life and its plasma half life in 
man ranges from 1.6-1.9 hour (Jarrott et al., 
1982; Raia et al., 1990; Levy et al., 1990). 
Moreover food may decrease oral absorption of 
captopril by up to 25-40% (Ohman et al., 1985; 
McEvoy 1996). 
The main problems associated with oral 
therapy include uneven bio-distribution 
throughout the body, a lack of drug targeting 
specificity, the necessity of a large dose to 
achieve high blood concentration and             
adverse side effects due to such high doses 
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(Dandagi et al., 2006). Captopril being an 
antihypertensive agent needs prolonged 
administration. Results of post market 
surveillance performed on captopril had shown 
that 4.9% of the patients had to discontinue 
therapy because of the adverse effects 
(Sweetman, 2005). The drug has low stability 
because of the oxidation, which converts the 
drug into captopril disulphide. A recent study 
had shown that the oxidation rate of captopril 
in dermal homogenates is significantly              
lower than that in intestinal homogenates 
(Zohu et al., 1994). This made captopril is a 
good candidate for transdermal delivery. 
 
METHODOLOGY  
Captopril  was a gift sample from Micro 
Lab Bangalore. Silver plates (purity 99.99%, 5 
mm diameters) were obtained from a goldsmith 
shop at Bangalore, India. Sodium Chloride AR, 
octanol , isopropyl alcohol, Silver Chloride, 
HPMC were obtained from SD Fine-Chem 
(Mumbai, India). Mixing of gel was carried in 
an electrical stirrer Remi model no. RQ- 
121/D. Cellulose membrane (9652 dialysis 
tubing Cut off point 12000 D) was purchased 
from Sigma- Aldrich, Germany. Iontophoretic 
DC source (digital display, current 0-10 mA, 
voltage 0-25 V) was purchased from                
C-tech Psu- 2510/lab Mumbai, India. Silver 
plates (purity 99.99%, 5 mm diameter) were 
obtained from a goldsmith shop of Bhopal. 
Iontophoretic diffusion cell was fabricated by 
Navin Scientific glass product, Bangalore, 
India, as per given specifications. Silver/silver 
chloride electrode was prepared as per the 
standard procedure (Banga, 1998). Silver wire 
(99.99% pure, 1.0 mm thickness) was used as 
connecting wire. All the reagents/chemicals 
used were of analytical grade. Experiments 
were conducted with ultra pure water 
(resistivity, 18.2 MW cm) obtained from Milli-
Q Academic System. 
 
Preparation of captopril gel  
Gel formulation (100 g) were prepared 
by soaking 5 g of HPMC overnight (12 h) in a 
part of solvent mixture (ethanol: propylene 
glycol: water in ratio of 50:30:20). The drug 2.5 
g separately dissolve in the same vehicle was 
added to the polymer dispersion. Glycerol (5 % 
v/v) was added as humectant and volume was 
adjusted to 100 mL by adding the vehicle. 
Finally the mixture was stirred using an 
electrical stirrer (500 rpm, 1 h) to ensure 
uniform transparency (Ghosh et al., 2009). 
 
Estimation of the drug (Content 
uniformity & in vitro diffusion study)  
Analysis of the samples were performed 
with Waters binary gradient HPLC system, 
equipped with 515 HPLC pump, PDA 
detector, C-18 column (ODS; 25 cm X 4.6 mm; 
5µm) at ambient temperature. The column was 
eluted with the mobile phase consisting of 
phosphate buffer (25 mM potassium 
dihydrogen ortho phosphate, pH 5.0) and 
acetonitrile at a ratio 88:12. A flow rate of 1 
mL/min was maintained, and the detection 
wavelength was 220 nm used. Retention times 
were recorded 8.4 minutes for captopril in our 
study. For making standard graph, working 
standards were prepared in phosphate buffer 
(5-80 mcg/mL) and injected into the column 
(20µL). A good linear relationship was 
observed between the concentrations and the 
peak area obtained with correlation coefficient 
(R2) 0.9995. Samples obtained from the 
diffusion and content analysis studies were 
injected into the column after suitable dilution 
and peak area were noted. The concentrations 
were determined by comparing the peak areas 
from the regression equation of the standard 
curve (Faruk and Ishar, 2009; Wu et al., 2000). 
 
Estimation of drugs in blood samples 
Blood was directly collected into vacuum 
tube (BD vacutainer TM) from rabbit ear vein 
and mixed with mixed with 0.05 mL of a 
solution of EDTA-3Na (0.2 M) and ascorbic 
acid (0.2 M) and centrifuged immediately at 
5000 rpm for 7 min at 4°C. A 1mL aliquot of 
plasma was added to a  screw-cap glass tube 
containing 0.1mL of a derivative agent 4-
bromophenacyl bromide (p- BPB, 2 mg/mL in 
acetonitrile) and 1mL of phosphate buffer (pH 
7.4). The tube was vortexed for 30 s and then 
left at room temperature for 30 min. After this, 
0.2mL 2 N HCl was added, and the resulting 
plasma samples were frozen at -20°C until 
assayed. Then 6mL of 1:1 mixture of ethyl 
acetate:benzene was used as extracting solvent. 
The tube was vortexed for 30 s and then 
shaken gently for 10 min. After centrifugation, 
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the organic layer was removed, and evaporated 
to dry under reduced pressure. The residue was 
reconstituted 7.4 pH phosphate buffer and 
aliquots of 0.02 mL were injected into the 
HPLC system (Wu et al., 2000; Popovici et al., 
2011) 
 
Drug content analysis 
Content uniformity of the gel formula-
tion was determined in cellulose membrane. 
irrelevant material was removed from the 
membrane, by washing the tubing in running 
water for 3-4 h and sulfur contaminations was 
removed by treating the tube with a 0.3 % 
(w/v) solution of sodium sulfide at 80º C for 1 
min. The tube was washed with hot water (60º 
C) for 2 min followed by acidification with 
0.04N sulfuric acid and rinsed with hot water to 
remove the acid. Gel formulation (2g) was 
taken in the treated membrane, kept in 50 mL 
beaker containing 50 mL phosphate buffer            
of pH 7.4 and stirred with magnetic stirrer.              
At the end of 24 h, sample was removed            
and estimated for drug content by HPLC 
(Ghosh et al., 2009).  
 
Preparation of pigskin membrane 
From a local abattoir, ear was obtained 
from freshly slaughtered pigs. The skin was 
removed carefully from the outer regions of the 
ear and separated from the underlying cartilage 
with a scalpel. After separating the full 
thickness skin, the fat adhering to the dermis 
side was removed using a scalpel and isopropyl 
alcohol. Finally the skin was washed with tap 
water and stored at -20°C in aluminum foil 
packing and was used within two days 
(Suwanpidokkul et al., 2004). 
 
Preparation of rabbit skin 
Prior permission was obtained from 
CPCSEA approved Institute Animal Ethics 
Committee (Registration No 1252/ac/09/ 
CPCSEA). The Rabbits were sacrificed by the 
I.V injection of chloroform (Taro et al., 2001). 
Skin samples were obtained from the back area 
of rabbits. The adherent fat and other visceral 
debris were removed. The dermal side of full 
thickness skin was soaked in buffer (phosphate 
buffer, pH 7.4) for 12 h at 4°C to equilibrate 
the skin and used on the same day. 
 
In vitro passive permeation studies 
The in vitro passive permeation studies 
were performed using vertical type Franz 
diffusion cell having a receptor compartment 
capacity of 10 mL. The excised skin was 
mounted between the half-cells with the dermis 
in contact with receptor fluid (Phosphate buffer 
pH 7.4)  and was equilibrated for 1 h. The area 
available for diffusion was about 1.21cm2. The 
donor cell was covered with an aluminum            
foil to prevent the evaporation of vehicle.           
The   fluid in the receptor compartment was 
maintained at 37±0.5°C. Under these 
conditions, the temperature at the skin surface 
was approximately 32°C. One mL of captopril 
gel was placed in the donor compartment. The 
entire assembly was kept on a magnetic stirrer 
and the solution in the receiver compartment 
was stirred continuously using a magnetic  
bead. The sample solution was withdrawn from 
the receptor compartment at regular intervals 
and assayed for drug content (Mutalik et al., 
2006). 
 
Procedure of iontophoretic diffusion 
For iontophoresis diffusion cell was 
modified as suggested by Glikfield et al., (1988). 
The apparatus essentially consisted of a glass 
molded large receiving chamber provided with 
two parallel ports on the topside and a 
sampling port on the side. Two upper 
chambers are made from open-ended 
cylindrical glass tubes, the outer diameters of 
which were equivalent to the inner diameter of 
the parallel ports. The lower 10 mm of these 
tubes were slightly constricted to allow a 
clearance of 1 to 1.5 mm on the side. This 
ensured easy fitting. After the skin was tied at 
this constricted end, the effective diameter 
increased and became exactly equal to inner 
diameter of the extended ports. Once slipped 
into parallel ports, they stay attached by glass 
joints forming two separate chambers with skin 
at the base. Both the skin touched the receptor 
solution at the same depth and each chamber 
housed one electrode. Once the battery was 
switched on, current flowed through the skin 
placed in anodal compartment into receiving 
solution below and reached the cathodal 
electrode through the skin tied to cathodal end.  
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Donor solution was filled in one of the top 
chambers depending on the polarity of the drug 
and the other serve as return electrode 
chamber. For our study, silver/silver chloride 
electrode was inserted into the donor 
compartment whereas silver plate was inserted 
into anodal chamber as return electrode. Direct 
current (0.5 mA cm-2) was used throughout 
experiment. The receptor fluid (5 mL) was 
withdrawn at regular intervals and replaced 
with fresh buffer to maintain sink condition. 
Samples were assayed by the U-V spectro-
photometrically.  
 
In vivo pharmacokinetic study 
Rabbits maintained in the CPCSEA 
approved Institute animal house and main-
tained in accordance with NIH guidelines were 
used. For pharmacokinetic studies the method 
of Anigbogu et al. was utilized (Anigbogu et al., 
2000). Healthy New Zealand rabbits of both 
sexes (body weight approximately 2 kg) were 
used. On the day of the experiment, hair was 
removed from two spots and skin areas were 
wiped with alcohol swabs. The animals were 
allowed to acclimatize for 30 min, in restrainers. 
For passive study, blank and drug gels were 
applied parallel to one another on the right 
dorsum separated by a distance of appro-
ximately 3 cm. In iontophoresis, the drug was 
delivered from cathodal electrode (silver/silver 
chloride) and blank gel was applied under the 
silver plate which served as return electrode 
(anode). The circuit was completed by 
connecting both the electrodes to the 
respective negative and positive poles of the 
constant power supply.  Studies were carried 
out at 0.1 mA/cm2 . The area for application  
of the electrode was 4 cm2. Time was noted  
for the application of gels and blood             
samples (1 mL) were collected every hour from 
the ear veins using vacuette tubes. The 
concentration was determined from the 
standard curve.  
 
Data analysis 
The cumulative amount permeated was 
plotted against time, and the slope of the linear 
portion of the plot was estimated as the steady 
state flux. Permeability coefficient and diffusion 
coefficient   were    calculated   using  following  
 
formulas (Sung et al., 2000): 
KP = JSS / Cd ……………. (1) 
D = KP h / K …………….. (2) 
where Kp represents permeability 
coefficient, Jss is the steady-state flux, Cd is the 
concentration of drug in donor compartment, 
D is the diffusion coefficient, K is the 
skin/vehicle partition coefficient and h the 
thickness of the skin. Flux enhancement was 
calculated by dividing iontophoretic steady state 




Statistical analysis was carried out using 
2- way ANOVA. The effect of concentration 
on steady state flux was separately evaluated by 
one-way ANOVA followed by Bonferroni’s 
test. (Bolton 1999) At 95% confidence 
intervals, p values less than 0.05 were 
considered to be significant. 
 
RESULTS AND DISCUSSION 
According to previous research of Wu et 
al (Wu et al., 1997) permeability of captopril had 
been evaluated by in a series of animal skins. 
Intrinsic skin permeability was found to be 
extremely low and it could not be detected in 
the rat plasma in an in-vivo experiment carried 
out by Hao et al., (Hao et al., 2000); This 
preliminary results indicate that skin 
permeation must be assisted with enhancement 
technique so attempt had been taken up in this 
study.  
Captopril, an  orally effective angioten-
sin-I converting enzyme inhibitor, is widely 
used intreatment of hypertension and conges-
tive heart failure but its oxidation in intestinal 
homogenates eliminates it with in 1.5 to 1.9 h 
(Jarrott et al., 1982; Raia, 1990; Levy et al., 1991) 
which is faster compared to its oxidation in 
dermal homogenates (Zhou et al., 1994). 
Consequently delivery of captopril as         
transdermal may be the better dosage               
form. Skin permeability of a drug is strongly 
influenced by its physicochemical parameters. 
According to Doh and coworkers (Doh, et             
al., 2003), drug candidates for transdermal           
delivery should have molecular weight around 
200–500 Da. Captopril having molecular  
weight   of   217.29    fits   into   the    category.  
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Physicochemical parameters of aptopril were 
investigated in our previous work, results   
showed good solubility in water (156.1mg/mL) 
and in 0.9%NaCl (145.57mg/mL) but 
experimentally determined partition coefficient 
(0.335) indicates poor lipophillicity (Jain et al., 
2011). Which indicates drug have less affinity 
towards lipid as compare to aqueous phase, but 
as it is the intrinsic property of molecule we can 
not change. Here attempt has been made to 
increase the permeation of captopril by the 
utilization of iontophoresis.  
After passive and iontophoretic 
permeation of captopril from a solutions, we 
found that iontophoresis could significantly 
enhance the in vitro permeation of the drugs 
compared to its passive diffusion, in our 
previous study (Jain et al., 2011). However, skin 
permeation of a drug from dosage form is 
much more complex than that from a solution. 
In a dosage form, drug stay in intimate contact 
with the excipients, this can influence its release 
profile. The concentration gradient of the         
free drug between the skin surface and       
plasma is the driving force of passive diffusion. 
Hence it is necessary to ensure that the           
drug is not irreversibly bound to the dosage 
form components and enough free drug 
concentration is available on the skin surface        
to   ensure   a    high    concentration   gradient.  
 
 
Figure 1. Comparison of passive and iontophoretic permeation of 
Captopril  in excised pigskin Data expressed as Mean  SD (n=3). 




Figure 2. Comparison of passive and iontophoretic permeation of 
Captopril  in excised Rabbit skin. Data expressed as Mean  SD 
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Gel formulation were prepared using hydroxyl 
propyl methyl cellulose. HPMC being a         
neutral polymer did not show any interaction 
with the drug. Drug content was found 
uniform. The measured viscosity of the gel was 
about 1.4 Pa/S for captopril (Brookfield 
viscometer, 12 rpm), suitable for transdermal 
application.  
Since one of the objectives of our study 
was to evaluate plasma concentration profile of  
drug in rabbits, it was necessary to have some 
basic idea about the permeability of drugs with 
respect to the rabbit skin also. Numbers of 
studies have reported that the barrier function 
of pigskin is close to the human skin 
(Suwanpidokkul et al., 2004) whereas the 
permeability of rabbit skin is much higher. 
Comparison of passive and iontophoretic 
permeation of both drugs from rabbit and pig 
skin were shown in figures Figure 1 and 2. 
Moreover the comparative data for pigskin and 
Rabbit skin also designed in figure figure 3 and 
4, results show that permeability of rabbit skin 
is much higher  than  compare to pigskin.  This  
was expected that rabbit skin is considered to 
be one of the most permeable among the 
laboratories animals (Hirvonen et al., 1991). As 
we assumed that rabbit skin with its higher 
follicular density and water content would  
favor iontophoresis better, it was right 
assumption after the study have performed. 
Permeation enhancement using iontophoresis  
was found to be higher in case of rabbit skin 
than pig skin.     
 
 
Figure 3. Comparison of Passive permeation of Captopril in 





Figure 4. Comparison of Iontophoretic permeation of 
Captopril in excised pig and rabbit skin. Data expressed as 
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Steady state fluxex, permeability coeffi-
cients, and enhancement ratio determined and 
provided in table I. Enhancement by ionto-
phoresis 6.265 folds for captopril  was reported 
in our study using rabbit skin it as slightly 
higher than that of pigskin. Figure 5 show    the   
plasma concentration profile of captopril  using 
passive diffusion and ionto-phoresis. It was 
seen that the captopril concentration after 
iontophoresis increase much rapidly than that 
of passive diffusion. Very less amount of 
captopril determined in plasma after passive 
diffusion but as expected it was considerably 
higher when iontophoresis  was used in the 
study.  
In our study the maximum plasma 
concentration of captopril was achieved   
909±28 ng/mL    at the end of 8th hour. 
Results showed   that   the   target  permeation  
 
 
rates for captopril could be achieved with the 
aid iontophoresis by increasing the area of 
application in an appreciable range. 
 
CONCLUSION 
The non compartmental analysis of the 
pharmacokinetic data indicate that to meet the 
demand of maintenance therapy for 60 kg 
individual 1488 μg of captopril must be 
supplied to the systemic circulation every hour 
(Wu et al., 1996).  
The in-vitro iontophoretic flux of 
captopril formulation through rabbit skin was 
found to be 251.471 g/hour.cm2  in our study. 
As the Patch in the market usually have wider 
area (10 cm2 and above), it can be expected to 
achieve the target. Overall results looked quite 




Figure 5. Plasma Concentration of Captopril after passive and 
iontophoretic administration of Captopril Gel in Rabbits. 
Data expressed as Mean  SD (n=3) 
 
 
Table I. Steady state fluxex, Permeability Coefficients, and enhancement ratio of Captopril in 
Rabbit and Pigskin from gel formulation. 
 
Parameters Process Pig Skin Rabbit skin 
Steady State Fluxes (g/hours. cm2) 
Passive 32.200 40.137 
Iontophoresis 162.185 251.471 
Permeability Coefficients (cm/h) 
Passive 1.28×10-3 1.605×10-3 
Iontophoresis 6.48×10-3 10.05×10-3 
Enhancement Ratio (R) (Ionto/Passive) 5.036 6.265 
Net Benefit of Iontophoresis (g/hrours. cm2) (Ionto-Passive) 129.985 211.333 
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